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Different expression of the plasminogen activation system in renal
thrombotic microangiopathy and the normal human kidney. Renal
thrombotic microangiopathy is characterized by glomerular and vascular
thrombosis. The persistancy of fibrin deposits may result from imbalance
between plasminogen activation and inhibition. In the present study, we
used immunohistochemistry and in situ hybridization techniques to deter-
mine the localization of urokinase-type (u-PA) and tissue-type (t-PA)
plasminogen activators, type I plasminogen activator inhibitor (PAT-i)
and membrane receptor for u-PA (uPA-R) antigen and their sites of
synthesis in renal thrombotic microangiopathy (N = 10) as compared to
acute tubular necrosis (N = 5) and normal human kidneys (N = 7). We
found an induction of PAl-i and uPA-R expression in glomeruli and in
arterial walls in renal thrombotic microangiopathy. In addition, the
induction of uPA-R expression was also found in some tubular epithelial
cells. In most cases, local synthesis of PAl-i and u-PA-R was confirmed by
in situ hybridization with the corresponding eDNA probes. In contrast,
using similar techniques PAl-I and uPA-R antigens and messenger RNAs
could not be detected in normal kidneys. In both renal thrombotic
microangiopathy and normal kidneys, t-PA mRNA was detected in large
amounts in all glomeruli and in vascular endothelial cells, but t-PA antigen
was only detected in a limited number of glomerular and arterial
endothelial cells, whereas it was strongly expressed by all venous endo-
thelial cells. Although u-PA antigen was found in almost all tubular
sections, u-PA mRNA was only found in tubular epithelial cells in the
deep cortex and the outer medulla. Our results indicate that there is an
up-regulation of PAl-i and u-PA-R expression in the glomeruli and in the
arterial walls of thrombotic microangiopathy. The local release of PAl-I
could play a role in the persistancy of fibrin deposition and the further
development of fibrotic lesions. Whether uPA-R plays a pathogenic role in
the development of glomerular and vascular lesions, or is involved in the
repair process of these lesions, remains to be elucidated.
Tissue-type (t-PA) and urokinase-type (u-PA) plasminogen
activators are two serine proteases that convert plasminogen into
plasmin, a trypsin-like serine protease of broad specificity, in-
volved in fibrinolysis [1] and extracellular matrix remodeling [2].
The binding of u-PA to its high affinity receptor (uPA-R) at the
cell surface accelerates the activation of plasminogen into plas-
mm, which in turn activates pro-u-PA to u-PA [3, 4]. Therefore,
uPA-R plays a crucial role for localizing u-PA at the cell surface
and for local plasmin formation. t-PA, which is produced by
endothelial cells, seems to be involved mainly in intravascular
thrombolysis, whereas u-PA is known to be implicated in the
extracellular matrix degradation [1, 21. The activity of both t-PA
and u-PA is controlled by plasminogen activator inhibitors of
which PAl-i appears to be the principal inhibitor [1].
In the murine kidney, using in situ zymography and in situ
hybridization methods, Sappino et al demonstrated that t-PA is
expressed in glomeruli and distal collecting ducts whereas u-PA is
produced by epithelial cells of the straight part of proximal and
distal tubules in the outer strip of the outer medulla [5]. A more
diffuse distribution of u-PA antigen was demonstrated by immu-
nohistochemistry, in epithelial cells of the medullary part of renal
tubules [61. It has also been demonstrated that PAl-i and uPA-R
are not detectable in the normal murine kidney but can be
induced after endotoxin administration [7, 8]. Tn the rat kidney,
PAl-i up-regulation has been reported after injection of nephro-
toxic serum [9, 10] or of Habu snake venom [11]. In the human
kidney, we previously reported that t-PA antigen is detectable by
indirect immunofluorescence in normal glomeruli and in endo-
thelial cells of renal arterioles [121, and Hasui et al showed that
u-PA antigen can be detected in almost all tubular sections [13].
To date PAl-i expression in the normal human kidney has not
been reported. However, we previously reported that PAl-i
antigen can be detected in fibrin deposits during renal thrombotic
microangiopathy and severe extracapillary glomerulonephritis
[141, and Wang et al showed that PAT-i is detected in the
endothelial cells of arterioles and arteries and also in infiltrating
cells of transplanted kidneys with severe vascular rejection [15].
Finally, to our knowledge uPA-R expression in the human kidney
has not been studied.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic
uremic syndrome (HUS), two syndromes with different clinical
presentations are characterized by a similar pathological lesion
named thrombotic microangiopathy [161. Fibrin deposition in
glomerular capillaries and small arteries and/or arterioles is the
main early finding. At a later stage, glomerular and arterial
fibro-proliferative lesions can be observed [16]. The mechanisms
of these lesions are unknown, but PAl-I accumulation may be
implicated, leading to a decrease of both fibrinolysis and extra-
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cellular matrix degradation. Although an elevated plasma PAl-i
level in patients with TIP [17] and HUS [18] has been reported,
the origin of PAl-I accumulated in glomeruli and renal vessels of
these patients [141 remains to be determined, since PAl-i may be
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released from endothelial cells of extrarenal vessels [19], aggre-
gated platelets [20], or glomerular and renal vascular cells.
Furthermore, it is not known if u-PA and uPA-R expressions are
modulated in thrombotic microangiophathy, although they may
be involved in angiogenesis, tissue degradation and repair [2].
To answer these questions, we used immunohistochemical and
in situ hybridization techniques to determine the distribution of
t-PA, u-PA, uPA-R and PAT-I and their sites of synthesis in the
kidney of patients with thrombotic microangiopathy as compared
to those of patients with acute tubular necrosis and of normal
human controls.
Methods
Materials
Thrombotic microangiopathy samples and normal human kidney.
Thrombotic microangiopathy samples were obtained by percuta-
neous renal biopsies from patients with HUS/TTP and biopsy-
proven thrombotic microangiopathy (N = 10). All patients (5
women, 5 men, median age of 37 years, range 19- to 58-years-old)
had a clinical TTP/HUS presentation following an acute diarrhea
(N = 7) which was hemorragic in three cases. The renal biopsy
was performed from 5 to 15 days after the occurrence of the first
symptoms, except in one case which was performed at day 45
when the patient was referred to our department for a recurrence
of hemolysis and renal failure. The mean plasma creatinine level
at the time of biopsy was 580 imol/liter (range 180 to 1430).
Except in one case, no patient had received fresh frozen plasma,
nor steroids before the renal biopsy. The pathological diagnosis
was performed by conventional light and immunofluorescence
microscopy, and nine patients had predominant glomerular le-
sions and one patient had predominant vascular lesions. In six
cases, tubular lesions were also observed. As the control with
tubular lesions but without glomerular involvment, we used the
biopsies of five patients with acute tubular necrosis. Normal
human kidney specimens were obtained from the normal part of
kidneys removed by nephrectomy for renal cell carcinoma (N =
7); the samples used were free of tumoral contamination by light
microscopy. All samples were frozen in liquid nitrogen immedi-
ately after biopsy and/or nephrectomy without prefixation for
immunohistochemical and in situ hybridization studies.
Reagents. The following antibodies were used: MuK4, a mono-
clonal anti-human u-PA antibody (Biopool, final concentration 5
p.gIml); PAM 3, a monoclonal anti-human t-PA antibody (Biopool,
final concentration 10 j.g/ml) and MAT 12, a monoclonal anti-
human PAT-i antibody (Monozyme Aps, final concentration 5
igIml). To analyze uPA-R expression, two monoclonal anti-
uPA-R antibodies (R2, R4) previously characterized and shown to
recognize different specific domains of uPA-R [21] and a poly-
clonal antibody against human uPA-R were used as previously
described [22]. Secondary antibodies and visualization reagents
were from Dako, Denmark; Sigma, USA; Amersham, UK and
Vector, USA.
The probes used were a 1,000-bp PstI insert of human PAT-i
eDNA (provided by Dr. David Loskutoff, Scripps Clinic and
Research Foundation, La Jolla, CA, USA), a BglII fragment of
the pPA 11 4B eDNA harboring 1948 bp of the human t-PA
eDNA, a 1200 bp BamHI fragment of human uPA-R eDNA
(provided by E.K.O. Kruithof, CHUV, Lausanne, Switzerland)
and a 600 bp EcoRl fragment of human u-PA eDNA (provided by
R.L. Medcalf, CHUV, Lausanne, Switzerland), as previously
described [23, 24]. The following reagents were used for in situ
hybridization studies: Random Primers DNA-Labeling Kit from
Bethesda Research Laboratory, USA; 35S-dCTP from ICN, Costa
Mesa, CA, USA.
Immunohistochemical studies
The fixation of anti-t-PA, anti-u-PA, anti-uPA-R (R2, R4)
monoclonal antibodies was detected and visualized by the alkaline
phosphatase anti-alkaline phosphatase complex technique
(APAAP) (Dakopatt) according to previously described methods
[25]. In the negative control, the primary antibody was omitted or
replaced by normal mouse IgGl (10 jsglml) from Dako.
The fixation of polyclonal anti-uPA-R and of monoclonal
anti-PAT-i antibodies was detected and visualized by the biotin-
streptavidin-peroxydase coupled technique. In brief, the tissue
sections were first incubated with the specific rabbit polyclonal
anti-u-PAR or mouse monoclonal anti-PAL-i antibody, and after
washing incubated with biotinylated anti-rabbit or anti-mouse
antibody (Vector). Then the tissue sections were incubated with
streptavidin coupled to peroxydase (Amersham, UK) which was
visualized by 3,3'-diaminobenzidine (DAB) in the presence of
H202 [26]. Sections were then counterstained with hematoxylin.
To decrease the background due to streptavidin binding to
endogenous biotin, tissue sections were preincubated with puri-
fied avidin and then with biotin before the incubation with the first
antibody as previously described [27]. The intensity of immuno-
histochemical staining of uPA-R, PAl-i, t-PA and u-PA in the
different renal structures (glomeruli, vessels, tubules) was assessed
independently by two observers and semiquantitatively graded as
—, +, ++ and +++ for no staining, light, moderate and strong
staining, respectively, in comparaison with normal human kidney
sections.
In situ hybridization studies
In situ hybridization was performed using 35S-labeled eDNA
probes as previously described [28]. The eDNA probes were
labeled by 35S-dCTP incorporation using the random primer
method. Slides were first rinsed in alcohol, dried at room temper-
ature, baked at 180°C for two hours and stored dust-free at room
temperature. Cryostat tissue sections (8 jim) were put on Un-
coated slides and fixed in 4% formaldehyde in PBS for 10 minutes,
rinsed in PBS and then dehydrated in graded alcohols and
air-dried. Slides were stored at —20°C until analyzed (less than 1
month). Hybridization was carried out without predigestion in the
mixture containing 0.2 ng/ml 35S-labeled probe plus 4 X SSC
(NaCI 3 M, trisodium citrate 0.3 M for 20 x SSC), I >< Denhart
(2% bovine serum albumin, 2% Ficoll, 2% polyvinylpyrrolidone
for 100 x Denhart), 50% desionized formamide, 250 ig/ml yeast
RNA, 500 sg/ml salmon sperm DNA and 5% dextran and
DL-Dithiothreitol. After denaturation of the eDNA probe by
heating at 100°C for five minutes, 10 jtl of hybridization solution
was applied to each section and then the sections were covered by
siliconed coverslips and incubated overnight at 45°C in a moist
chamber. After the hybridization, the sections were successively
washed in 40% formamide 4 >< SSC at 45°C, and then 2 >< SSC at
60°C, 1 x SSC, 0.5 x SSC and 0.2 x SSC at room temprature for
a total of four hours. The sections were dehydrated in graded
alcohols and air-dried. Then the sections were dipped in 50%
NTB2 emulsion (Eastman Kodak, Rochester, NY, USA) in water
and exposed in a black box at 4°C for 14 days. The autoradiograph
was developed in Kodak D19 for three minutes, fixed in Kodak
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Fig. 1. Localization of PAl-I and uPA-R antigens in renal thrombotic microangiopathy by immunohisiochemical studies (original magnifications: A, C, F
10 X 25; B, D, E 10 X 50). By biotin-streptavidin-peroxydase coupled technique, a strong PAl-i staining was observed in glomeruli (A) and in arterial
endothelial cells (B) of renal thrombotic microangiopathy. uPA-R was also detected, by APAAP technique, in glomeruli (C), in vascular walls (D) and
in tubular epithelial cells (C and E) especially on the surface of some desquamated epithelial cells (E). Incubation with normal mouse IgGi as primary
antibody showed no staining (F). Publication of this figure in color was made possible by a grant from Produits Roche, Neuilly-sur-Seine, France.
"rapid fix" and counterstained with hematoxylin. The negative
controls were performed by preincubation of the sections with 100
j.sg/ml ribonuclease A (RNase) before the incubation with 35S-
labeled eDNA probe or incubation without the 35S-labeled probe.
Results
Immunohistochemical studies
As shown in Figures 1 and 2 and in Table 1, with anti-PAT-i
antibody, an intense staining was found in glomeruli and in
arterial walls, especially in endothelial cells in 7 Out of 10 cases of
thrombotic microangiopathy. No PAT-i was detected in normal
human kidneys nor in the cases of acute tubular necrosis. Simi-
larly, a strong uPA-R expression was observed in glomeruli and in
arterial walls of all thrombotic microangiopathy cases. In addition,
an intense membrane uPA-R expression was also found on some
tubular epithelial cells, particularly at the surface of desquamating
epithelial cells. A similar tubular uPA-R expression was observed
in the five cases of acute tubular necrosis. In these cases, uPA-R
was only found at the surface of tubular epithelial cells, especially
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Fig. 2. Detection oft-PA, u-PA, PAl-I and uPA-R in normal human kidney by immunohistochemical studies (original magnifications: A, B 10 X 50; C, D,
E, F 10 >< 25). In normal human kidney, by APAAP technique a faint endothelial t-PA expression was detected in the glomerulus (A), and an intrarenal
artery (B), but a large amount of t-PA antigen was detected in venous endothelial cells (C). u-PA was mainly detected in tubular epithelial cells,
predominantly at the brush border of convoluted proximal tubules (D). PAT-i (E) and uPA-R (F) could not be detected in normal human kidneys.
in cells desquamating in the tubular lumen, but not in glomerular
cells. Some interstitial infiltrating cells were also stained by
anti-uPA-R antibody in thrombotic microangiopathy and acute
tubular necrosis (data not shown). The three different anti-uPA-R
antibodies gave a similar pattern in all cases. In contrast, no
uPA-R antigen could be detected in the normal human kidneys
whatever the antibody used. Only few glomerular and arterial
endothelial cells weakly expressed t-PA both in thrombotic mi-
croangiopathy and in normal human kidneys. In contrast, t-PA
antigen was strongly expressed by venous endothelial cells in these
two conditions. In addition, in the renal thrombotic microangi-
opathy, some infiltrating cells were also labeled by anti-t-PA
antibody (data not shown). u-PA antigen was detected in all
tubular sections in thrombotic microangiopathy and in normal
human kidney. This expression was more pronounced at the brush
border of convoluted proximal tubules. In addition, some glomer-
ular podocytes were also faintly stained by anti-u-PA antibody.
In situ hybridization studies
As shown in Figure 3, glomerular and arterial expression of
PAl-i mRNA was detected in thrombotic microangiopathy in
three out of four cases studied, whereas PAl-i mRNA was never
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Table 1. Results of immunohistochemical analysis of uPA-R, PAl-i, u-PA and t-PA antigens on renal biopsies
uPAR PAl-I u-PA tPA
0 T A 0
— + +++ — + — + +++
— — — --- — +++ — — — ++
— — — — — — + +++ — — ++
— + — + +
— — — — — — + -ft + — — ++
— — ++ — — — ++
— — — — — +++ — — ++
+++ + — + + +++ — — —
— + —
— + ++ — +
— + + ++ — +
5 + — — + — — + — — —
6 ++ + f-F — + — ++ +++ + + — +
7 +++ + — — + — +++ — — +
Acute tubular
necrosis
— +
— +
The localization of uPA-R, PAl-I, u-PA and t-PA
(A) or veinules (V).
detected in normal human kidneys. Similarly, glomerular expres-
sion of uPA-R mRNA was also observed in thrombotie mieroan-
giopathy in three out of seven cases studied. Tn addition, uPA-R
mRNA could be detected in some desquamated tubular cpithclial
cells in correlation with the immunohistoehemical findings. These
glomerular and tubular uPA-R mRNA expressions were never
detected in normal human kidneys. Compared to normal human
kidneys, in which a strong and homogeneous expression of t-PA
mRNA was found in all glomeruli, we found a decreased glomer-
ular t-PA mRNA expression in thrombotic microangiopathy
kidney in four out of six cases. In addition, t-PA mRNA was
detected in endothelial cells of renal vessels in both thrombotic
microangiopathy and normal human kidneys. By this technique,
we did not find t-PA mRNA in any tubular sections. Finally, u-PA
mRNA expression was detected only in some tubular sections, in
the deep cortex and the outer medulla, corresponding to the
straight parts of proximal and distal tubules both in thrombotic
microangiopathy and in normal human kidneys. No significant
signal was found in the glomeruli and the arterioles nor in
proximal and distal convoluted tubules, The specificity of the
signals obtained with the different probes was confirmed by the
absence of signal when tissue sections were treated with RNase
before the incubation with the labeled probe.
Discussion
In the present study, by immunohistochemistry and in situ
hybridization studies, we investigated the expression of the plas-
minogcn activation system in renal thrombotic microangiopathy
as compared to acute tubular necrosis in which tubular, but not
glomerular injury is observed and to normal human kidneys. We
demonstrate for the first time an intrarenal up-regulation of
PAT-I and uPA-R expression in most of the cases of thrombotie
microangiopathy. We also show that no PAl-i and uPA-R expres-
sion can be detected in the normal human kidney. In addition, we
— — +++
— + +++
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
found a decreased glomerular t-PA mRNA expression in some
cases of thrombotic microangiopathy whereas u-PA expression
was not significantly altered as compared to normal human
kidneys.
In thrombotic mieroangiopathy, but not in acute tubular necro-
sis nor in the normal human kidney, the induction of PAI-T and
uPA-R expression was mainly found in glomeruli and in vascular
walls of arterioles with thrombotic and/or proliferative lesions.
Interestingly, uPA-R and PAT-I antigens were detected in almost
all the cases, whereas uPA-R mRNA and PAT-T mRNA were
detected in some but not all the cases, suggesting that the
up-rcgulation of uPA-R and PAT-i mRNA is transient and that
the uPA-R and PAT-I antigens have a longer half-life than the
corresponding mRNA. The present study confirms and extends
our previous findings [141 showing that the accumulation of PAT-i
in glomeruli and in vascular walls results from the local overex-
pression of PAT-i by the resident cells of glomeruli and vascular
walls. This excess of PAT-I could inhibit local t-PA activity and
thus promote the glomerular and vascular fibrin accumulation
which is observed in thrombotic microangiopathy. t-PA antigen
was mainly detected in venous endothelial cells and to a lesser
extent in glomeruli and in arterial endothelial cells. In contrast,
t-PA mRNA was strongly expressed in glomeruli as well as in all
vascular endothelial cells suggesting a rapid release of newly
synthetizcd t-PA from glomeruli and arteriolar endothelial cells.
Similar sites of synthesis were reported in the murine kidney [I
Our results also show a decreased glomerular t-PA mRNA
expression in some eases of thrombotie mieroangiopathy. How-
ever, quantitation of the signal obtained by in situ hybridization is
difficult and direct measurements of t-PA mRNA would be
necessary to confirm this result. A decreased t-PA synthesis,
combined with an up-regulation of PAl-i synthesis is likely to
induce a decrease in local fibrinolytie activity.
Tnduetion of uPA-R expression in glomerular and vascular
Case 0 T A U T A
Normal
controls
Thrombotic
microangiopathy
1
2
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7
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2 + —
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10 + —
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antigens in the different kidney structures is reported: glomeruli (G), tubules (T) and arterioles
-
, •k2 - •5W 4 t*
-.S SU.
fr L. •.It, - 45. 5
a
P
S.
SI. 4'
5, -
s1 •St,t4
S
I FI a
'•.:t
0' j43
S
a
a 0'I
B' 4A as-a.
•
-S
rap' 4S
S
I.,. u
• i.S. ,n
S. cI, 'rji S.
"c--'w
[F a
S
S
S_S
a
S
v'S
— ?5. .4S.'
.5 5
• a
Ii"
S
S
•S
a
75
S
e.I.:,,
(S.
.l.
S •,• 'S asF 4 . SPS a. p
,. I.. •
.4.
31.4 •J I
•es, •.., as's 5
• - aft'
-S
I
- _ F-,
S5, I
.! 1f •
SSpS •t
Sa
• It.
•
-I •5
— % 5%1
-
I
SIPSf I'tS.,. 4I
S.
4.5 a
• •jue
'S
—S I_bMt
— S
'C..
Fig. 3. Localization of PAl-I and uPA-R mRNA in renal thrombotic microangiopathy by in situ hybridization (original magnifications: A, B, C, D, E, G,
H, 10 >< 25; F 10 x 50). A strong PAl-i mRNA expression was detected in glomerulus (A, bright field; C, dark field) and in arteries (E). A weak
glomerular uPA-R mRNA expression was detected in renal thrombotic microangiopathy (B, bright field; D, dark field). Some tubular epithelial cells
were also found to express u-PA-R mRNA (F). No specific signal was detected if tissue sections were treated with RNase before the incubation with
the 35S-labeled PAT-I (G) or uPA-R (H) probe. Only the background signal is observed.
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Fig. 4. Localization oft-PA, u-PA, PAl-i and uPA-R mRNA in normal human kidneys (original magnification 10 X 25). A strong glomerular expression
of t-PA mRNA was detected (A) and the specific signal was suppressed if the tissue sections were pretreated with RNAse before hybridization with the
35S labeled t-PA probe (B). u-PA mRNA was detected in tubular epithelia! cells in the deep cortex and the outer medulla (C) and no specific signal
was detected on RNAse pretreated sections (D). PAT-i (E) and uPA-R mRNA (F) were not detectable in normal human kidneys by in situ hybridization.
Only the background signal is observed.
endothelial cells and in tubular epithelial cells as well as in some
inflammatory cells in thrombotic microangiopathy indicates an
activated phenotype of these cells. In vivo, the induction of uPA-R
expression has been reported in tumor cells at invasive foci and in
tumor-associated macrophages, fibroblasts and endothelial cells
[22, 29—31]. It has been recently reported that uPA-R expression,
which is undetectable in the normal murine kidney, is up-
regulated after endotoxin administration [8], suggesting a role of
endotoxin itself or of cytokines such as IL-i and TNF-a in the
induction of u-PA-R expression. The effect of uPA-R expression
may be beneficial by promoting cell-surface plasminogen activa-
tion and fibrin degradation. Furthermore, uPA-R has been shown
to bind uPA-PAI-1 complexes which are then internalized and
degraded within the cells [32], suggesting that uPA-R could also
enhance the local fibrinolytic activity by promoting PAT-i degra-
dation. Tn addition, the cell surface expression of uPA-R may
2018 Xu et al: Plasminogen activation and thrombotic microangiopathy
promote matrix degration, cell adhesion and proliferation [33—35],
all processes required for the formation of proliferative and
infiltrating lesions [1, 21. Interestingly, both in thrombotic mi-
croangiopathy and in acute tubular necrosis, the presence of uPA
on almost all tubular sections and the overexpression of uPA-R
without PAl-I expression in some tubular epithelial cells, partic-
ularly at the surface of desquamating cells, may indicate a role of
uPA-R and u-PA in the process of cell detachment from the
basement membrane. The brush border of proximal tubular
epithelial cells was particularly strongly stained with anti-uPA
antibodies. In contrast, u-PA mRNA was only found in tubular
epithelial cells of the deep cortex and the outer medulla. These
latter results are also in agreement with the study of Sappino et al
in the murine kidney [5]. The absence of u-PA mRNA in
convoluted proximal tubules suggests that u-PA antigen that we
detected in these cells is not synthesized in situ. A likely explana-
tion may be that u-PA, filtrated throught the glomerulus reaches
the proximal tubule and binds to gp330, a 330 kDa glycoprotein
that is located at the apical membrane of proximal epithelial cells
and is involved in u-PA uptake [36].
In conclusion, in the present study, using immunohistochemis-
try and in situ hybridization methods, we demonstrate an induc-
tion of PAT-i and uPA-R expression in glomeruli and vascular
walls during renal thrombotic microangiopathy. Using the same
techniques, these molecules could not be detected in normal
human kidneys. The induction of PAL-i expression in glomeruli
and arterial walls could play a role in the persistancy of fibrin. The
overexpression of uPA-R in glomerular and vascular cells suggests
an activated phenotype of these cells, but the exact role of uPA-R
in the process of thrombotic microangiopathy remains to be
investigated.
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